bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
Authors: Manara Maria Cristina , Valente Sergio , Cristalli Camilla , Nicoletti Giordano , Landuzzi Lorena , Zwergel Clemens , Mazzone Roberta , Stazi Giulia , Arimondo Paola B. , Pasello Michela , Guerzoni Clara , Picci Piero , Nanni Patrizia , Lollini Pier-Luigi , Mai Antonello , Scotlandi Katia
Published: April 2023

Silencing of DNMTs inhibits cell proliferation, induces osteoblastic differentiation and enhances DXR sensitivity
Supplementary Figure S1 from First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer
Authors: Capasso Anna , Bagby Stacey M. , Dailey Kyrie L. , Currimjee Naomi , Yacob Betelehem W. , Ionkina Anastasia , Frank Julie G. , Kim Deog Joong , George Christina , Lee Young B. , Benaim Ely , Gittleman Brian , Hartman Sarah J. , Tan Aik Choon , Kim Jihye , Pitts Todd M. , Eckhardt S. Gail , Tentler John J. , Diamond Jennifer R.
Published: April 2023

Survival curves for RX-5902 treatment and Abraxane and Vehicle control in vivo
Supplementary Data from Blood Interactions, Pharmacokinetics, and Depth-Dependent Ablation of Rat Mammary Tumors with Photoactivatable, Liposomal Doxorubicin
Authors: Carter Kevin A. , Luo Dandan , Geng Jumin , Stern Stephan T. , Lovell Jonathan F.
Published: April 2023

Supplementary Data file includes 4 tables, 3 Figures, and extended MS methods. Table S1 reports endotoxin levels in liposomes made. Table S2 reports liposome physical parameters. Table S3 shows iCb3 generation. Table S4 shows pharmacokinetic parameters. Figure S1 shows predicted light attenuation vs observed drug delivery at different tumor tissue depths. Figure S2 shows tumor growth curves. Figure S3 shows eschar rating scale photos.
Supplementary Table S1 from Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept
Authors: Peyrode Caroline , Weber Valérie , Voissière Aurélien , Maisonial-Besset Aurélie , Vidal Aurélien , Auzeloux Philippe , Gaumet Vincent , Borel Michèle , Dauplat Marie-Mélanie , Quintana Mercedes , Degoul Françoise , Rédini Françoise , Chezal Jean-Michel , Miot-Noirault Elisabeth
Published: April 2023

Alkylation rate of Mel-QA and Mel obtained in the NBP assay
Supplementary Figure Legends from Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept
Authors: Peyrode Caroline , Weber Valérie , Voissière Aurélien , Maisonial-Besset Aurélie , Vidal Aurélien , Auzeloux Philippe , Gaumet Vincent , Borel Michèle , Dauplat Marie-Mélanie , Quintana Mercedes , Degoul Françoise , Rédini Françoise , Chezal Jean-Michel , Miot-Noirault Elisabeth
Published: April 2023

List and legends of 3 supplementary files
Supplementary Fig. S1 from Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept
Authors: Peyrode Caroline , Weber Valérie , Voissière Aurélien , Maisonial-Besset Aurélie , Vidal Aurélien , Auzeloux Philippe , Gaumet Vincent , Borel Michèle , Dauplat Marie-Mélanie , Quintana Mercedes , Degoul Françoise , Rédini Françoise , Chezal Jean-Michel , Miot-Noirault Elisabeth
Published: April 2023

Characterization of Mel-QA
Supplementary figure 3 from TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
Authors: Rodríguez-Ruiz María E. , Rodríguez Inmaculada , Mayorga Lina , Labiano Tania , Barbes Benigno , Etxeberria Iñaki , Ponz-Sarvise Mariano , Azpilikueta Arantza , Bolaños Elixabet , Sanmamed Miguel F. , Berraondo Pedro , Calvo Felipe A. , Barcelos-Hoff Mary Helen , Perez-Gracia Jose L. , Melero Ignacio
Published: April 2023

FACS analyses on cell suspensions (n=4) derived from non-irradiated MC38-derived tumors
Supplementary Figure 1 from Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma
Authors: Renziehausen Alexander , Tsiailanis Antonis D. , Perryman Richard , Stylos Evgenios K. , Chatzigiannis Christos , O'Neill Kevin , Crook Timothy , Tzakos Andreas G. , Syed Nelofer
Published: April 2023

Supplementary Figure 1 showing 1H-NMR spectra of Calix, TMZ and TMZ@Calix complex
Figure S5 from Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma
Authors: Xie Xiaoling , Chen Yiran , Hu Yuxing , He Yanjie , Zhang Honghao , Li Yuhua
Published: April 2023

Representative flow cytometric analysis images (A) and relative quantification (B) of PD-1+ expression on CD3+CD8+ T cells. These data demonstrated that the Eps8cocktail@len treatment downregulated PD-1 expression on CD3+CD8+ T cells in the tumors. All data represent the mean {plus minus} SD (n = 3). *P < 0.05 and **P < 0.01.
Supplementary Table 2 from Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Authors: Nisa Lluís , Francica Paola , Giger Roland , Medo Matúš , Elicin Olgun , Friese-Hamim Manja , Wilm Claudia , Stroh Christopher , Bojaxhiu Beat , Quintin Aurélie , Caversaccio Marco D. , Dettmer Matthias S. , Buchwalder Mélanie , Brodie Tess M. , Aebersold Daniel M. , Zimmer Yitzhak , Carey Thomas E. , Medová Michaela
Published: April 2023

Supplementary Table 2 provides odds ratio per protein (CyTOF measurements)
Supplemental Figure 7 from CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer
Authors: Xiang Jingyu , Hurchla Michelle A. , Fontana Francesca , Su Xinming , Amend Sarah R. , Esser Alison K. , Douglas Garry J. , Mudalagiriyappa Chidananda , Luker Kathryn E. , Pluard Timothy , Ademuyiwa Foluso O. , Romagnoli Barbara , Tuffin Gérald , Chevalier Eric , Luker Gary D. , Bauer Michael , Zimmermann Johann , Aft Rebecca L. , Dembowsky Klaus , Weilbaecher Katherine N.
Published: April 2023

Supplemental Figure 7. Effect of POL5551 combined with eribulin on hematopoietic cells
Supplementary Methods from Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Authors: Nisa Lluís , Francica Paola , Giger Roland , Medo Matúš , Elicin Olgun , Friese-Hamim Manja , Wilm Claudia , Stroh Christopher , Bojaxhiu Beat , Quintin Aurélie , Caversaccio Marco D. , Dettmer Matthias S. , Buchwalder Mélanie , Brodie Tess M. , Aebersold Daniel M. , Zimmer Yitzhak , Carey Thomas E. , Medová Michaela
Published: April 2023

Supplementary Methods
Supplemental Figure 6 from CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer
Authors: Xiang Jingyu , Hurchla Michelle A. , Fontana Francesca , Su Xinming , Amend Sarah R. , Esser Alison K. , Douglas Garry J. , Mudalagiriyappa Chidananda , Luker Kathryn E. , Pluard Timothy , Ademuyiwa Foluso O. , Romagnoli Barbara , Tuffin Gérald , Chevalier Eric , Luker Gary D. , Bauer Michael , Zimmermann Johann , Aft Rebecca L. , Dembowsky Klaus , Weilbaecher Katherine N.
Published: April 2023

Supplemental Figure 6. Mobilization of leukocytes with POL5551.
Supplemental Figure 5 from CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer
Authors: Xiang Jingyu , Hurchla Michelle A. , Fontana Francesca , Su Xinming , Amend Sarah R. , Esser Alison K. , Douglas Garry J. , Mudalagiriyappa Chidananda , Luker Kathryn E. , Pluard Timothy , Ademuyiwa Foluso O. , Romagnoli Barbara , Tuffin Gérald , Chevalier Eric , Luker Gary D. , Bauer Michael , Zimmermann Johann , Aft Rebecca L. , Dembowsky Klaus , Weilbaecher Katherine N.
Published: April 2023

Supplemental Figure 5. Eribulin dose ranging study.
Supplemental Figure 1-2 from CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer
Authors: Xiang Jingyu , Hurchla Michelle A. , Fontana Francesca , Su Xinming , Amend Sarah R. , Esser Alison K. , Douglas Garry J. , Mudalagiriyappa Chidananda , Luker Kathryn E. , Pluard Timothy , Ademuyiwa Foluso O. , Romagnoli Barbara , Tuffin Gérald , Chevalier Eric , Luker Gary D. , Bauer Michael , Zimmermann Johann , Aft Rebecca L. , Dembowsky Klaus , Weilbaecher Katherine N.
Published: April 2023

Supplemental Figure 1-2. Supplemental Figure 1: Pharmacology of POL5551; Supplemental Figure 2: Correlation of CXCR4 expression in primary tumor with survival in patients
Figure S6 from Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy
Authors: Chen Li-Hsien , Sun Yuan-Ting , Chen Yih-Fung , Lee Mei-Yi , Chang Lian-Yun , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

The therapeutic potential of 5-HD in mouse model
Figure S4 from Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy
Authors: Chen Li-Hsien , Sun Yuan-Ting , Chen Yih-Fung , Lee Mei-Yi , Chang Lian-Yun , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

Neuroprotective drugs screened from the image-based high-content platform
Figure S4 from Targeting of BRM Sensitizes BRG1-Mutant Lung Cancer Cell Lines to Radiotherapy
Authors: Zernickel Erika , Sak Ali , Riaz Assad , Klein Diana , Groneberg Michael , Stuschke Martin
Published: April 2023

BRM knock-down has no effect on cell cycle distribution in A549 (BRG1-) cells
Supplementary Figure S3 from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Authors: Bhagwat Shripad V. , McMillen William T. , Cai Shufen , Zhao Baohui , Whitesell Matthew , Shen Weihua , Kindler Lisa , Flack Robert S. , Wu Wenjuan , Anderson Bryan , Zhai Yan , Yuan Xiu-Juan , Pogue Meghann , Van Horn Robert D. , Rao Xi , McCann Denis , Dropsey Andrew J. , Manro Jason , Walgren Jennie , Yuen Eunice , Rodriguez Michael J. , Plowman Gregory D. , Tiu Ramon V. , Joseph Sajan , Peng Sheng-Bin
Published: April 2023

Inhibition of downstream signaling by LY3214996 in a BRAF-mutant A375 melanoma cells (A) and MEK1 mutant SW48 colorectal cancer cells (B).
Supplementary Methods, Supplementary Table S1, and Supplementary Figures S1-S2 from The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active-Site Catalytic Metals in PPP5C
Authors: D'Arcy Brandon M. , Swingle Mark R. , Papke Cinta M. , Abney Kevin A. , Bouska Erin S. , Prakash Aishwarya , Honkanen Richard E.
Published: April 2023

Table S1. Comparison of the PPP5C-LB-100 model with known structures of PPP5C-inhibitor complexes; Supplementary Figure S1 shows. Isomorphous difference Fourier (Fo-Fo) map of PPP5C-LB-100 - PPP5C-4TE, created in PHENIX, contoured at 3Ïƒ. Red and green coloring indicate negative and positive density, respectively. The red arrow highlights the negative density for the C5 methyl in 4TE that is not present in LB-100. From the map, there is no apparent positive density for the methylpiperazine ring of LB-100; Supplementary Figure S2 shows the mass spectrometry analysis of LB-100 revealing a mass of 269.15, which corresponds to the mass of protonated LB-100; theoretical mass of 268.31.
Supplementary Table 12 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

Results from the siRNA kinase and tumour suppressor dasatinib resistance screen, see also Figure 5
Supplementary Table S5 from Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
Authors: Azuara Daniel , Santos Cristina , Lopez-Doriga Adriana , Grasselli Julieta , Nadal Marga , Sanjuan Xavier , Marin Fátima , Vidal Joana , Montal Robert , Moreno Victor , Bellosillo Beatriz , Argiles Guillem , Elez Elena , Dienstmann Rodrigo , Montagut Clara , Tabernero Josep , Capellá Gabriel , Salazar Ramon
Published: April 2023

Estimation of the prediction quality of mutational status for treatment response. First column (AUC) indicates the Area Under the Curve as a prediction quality measure for all mutation groups. As expected, the AUC increases for lower mutation frequency cut-off. Then, a symmetric matrix for each mutation group with five columns, one column for each cut-off, reports the p-values for all curves comparisons. Highlighted in black the p-values that indicate correlative comparison. Highlighted in red are the p-values close to significant levels that correspond to the comparison between 1% and 1.5% cut-off value. Differences between cut-off of 1% and 1.5% are bigger than differences between the other correlative cut-off comparisons. P-values are close to significance level with a confidence of 90%.
Supplementary Figures from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

Supplementary Figure 1 ARID1A mutations in the panel of OCCC tumour cell line models with corresponding protein expression. Supplementary Figure 2 Un-cropped western blots from main and supplementary figures. Supplementary Figure 3 ARID1A selective effects from the high throughput drug screen. Supplementary Figure 4 Inhibitors of the PI3K/mTOR signalling pathway in the panel of OCCC cell lines and ARID1A selectivity. Supplementary Figure 5 Dasatinib is a synthetic lethal drug in ARID1A mutant OCCC tumour cell line models - see also Figure 2. Supplementary Figure 6 Dasatinib sensitivity in ARID1A mutant isogenic HCT116 colorectal tumour cell line model. Supplementary Figure 7 Dasatinib siRNA screen results. Supplementary Figure 8 Apoptosis assay in four OCCC cell line models, see also Figure 4. Supplementary Figure 9 Dasatinib sensitivity in ARID1A mutant OCCC is dependent upon G1/S checkpoint effectors, see also Figure 5. Supplementary Figure 10 Determining the optimal method of dasatinib delivery in vivo.
Supplementary Table S2 from Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
Authors: Azuara Daniel , Santos Cristina , Lopez-Doriga Adriana , Grasselli Julieta , Nadal Marga , Sanjuan Xavier , Marin Fátima , Vidal Joana , Montal Robert , Moreno Victor , Bellosillo Beatriz , Argiles Guillem , Elez Elena , Dienstmann Rodrigo , Montagut Clara , Tabernero Josep , Capellá Gabriel , Salazar Ramon
Published: April 2023

Panel of mutations, primers and probe sequences
Supplementary Figures 1-9 and Supplementary Tables 1-8 from Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer
Authors: Zhang Zhenfeng , Peng Huixin , Wang Xiaojie , Yin Xia , Ma Pengfei , Jing Ying , Cai Mei-Chun , Liu Jin , Zhang Meiying , Zhang Shengzhe , Shi Kaixuan , Gao Wei-Qiang , Di Wen , Zhuang Guanglei
Published: April 2023

Supplementary Figure 1. High-throughput small-molecule screen in ovarian cancer cells. Supplementary Figure 2. Inhibition of ovarian cancer cell viability by JQ1 and THZ1. Supplementary Figure 3. Cell cycle and apoptosis analysis upon THZ1 treatment. Supplementary Figure 4. Impact of THZ1 on tumor xenograft models, normal cells and lung cancer cells. Supplementary Figure 5. Effects of CDK7 depletion in ovarian cancer cell lines. Supplementary Figure 6. Effects of individual CDK depletion in ovarian cancer cell lines. Supplementary Figure 7. Hazard ratio for each CDK as a predictor of overall survival in ovarian cancer. Supplementary Figure 8. Gene set enrichment analysis in THZ1 versus DMSO treated ovarian cancer cells. Supplementary Figure 9. Super-enhancer-associated genes identified in COV 413B, OVCA420 and SKOV3 cells. Supplementary Table 1. Percentage of viability inhibition with 181 inhibitors. Supplementary Table 2. IC50 of THZ1 in ovarian cancer cell lines. Supplementary Table 3. EOC patient cohort for CDK7 IHC. Supplementary Table 4. THZ1-inhibited gene transcripts. Supplementary Table 5. Functional annotation analysis by DAVID. Supplementary Table 6. Super-enhancer analysis of COV 413B. Supplementary Table 7. Super-enhancer analysis of OVCA420. Supplementary Table 8. Super-enhancer analysis of SKOV3.
Supplemental Table 1 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
Authors: Giulino-Roth Lisa , van Besien Herman J. , Dalton Tanner , Totonchy Jennifer E. , Rodina Anna , Taldone Tony , Bolaender Alexander , Erdjument-Bromage Hediye , Sadek Jouliana , Chadburn Amy , Barth Matthew J. , Dela Cruz Filemon S. , Rainey Allison , Kung Andrew L. , Chiosis Gabriela , Cesarman Ethel
Published: April 2023

Hsp90 client proteins identified by PU-H71 high affinity capture
Supplementary Figure S5 from AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Authors: Min Ahrum , Im Seock-Ah , Jang Hyemin , Kim Seongyeong , Lee Miso , Kim Debora Keunyoung , Yang Yaewon , Kim Hee-Jun , Lee Kyung-Hun , Kim Jin Won , Kim Tae-Yong , Oh Do-Youn , Brown Jeff , Lau Alan , O'Connor Mark J. , Bang Yung-Jue
Published: April 2023

ATM inhibition sensitizes resistant cells to AZD6738
Table S6 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
Authors: Santos Cristina , Azuara Daniel , Garcia-Carbonero Rocio , Alfonso Pilar Garcia , Carrato Alfredo , Elez Mª Elena , Gomez Auxiliadora , Losa Ferran , Montagut Clara , Massuti Bartomeu , Navarro Valenti , Varela Mar , Lopez-Doriga Adriana , Moreno Victor , Valladares Manuel , Manzano Jose Luis , Vieitez Jose Maria , Aranda Enrique , Sanjuan Xavier , Tabernero Josep , Capella Gabriel , Salazar Ramon
Published: April 2023

Survival analysis according to mutational status in the study population (N = 580)
Table S2 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
Authors: Santos Cristina , Azuara Daniel , Garcia-Carbonero Rocio , Alfonso Pilar Garcia , Carrato Alfredo , Elez Mª Elena , Gomez Auxiliadora , Losa Ferran , Montagut Clara , Massuti Bartomeu , Navarro Valenti , Varela Mar , Lopez-Doriga Adriana , Moreno Victor , Valladares Manuel , Manzano Jose Luis , Vieitez Jose Maria , Aranda Enrique , Sanjuan Xavier , Tabernero Josep , Capella Gabriel , Salazar Ramon
Published: April 2023

Mutations detected by cobas®, therascreen® pyro and highly-sensitive dPCR
Supplementary Figure Legends from Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53
Authors: Karan Goutam , Wang Huaiyu , Chakrabarti Amit , Karan Sukanya , Liu Zhigang , Xia Zhiqiang , Gundluru Mahesh , Moreton Stephen , Saunthararajah Yogen , Jackson Mark W. , Agarwal Mukesh K. , Wald David N.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure legend from Secretory TRAIL-Armed Natural Killer Cell–Based Therapy: In Vitro and In Vivo Colorectal Peritoneal Carcinomatosis Xenograft
Authors: Song Xinxin , Hong Se-Hoon , Kwon William T. , Bailey Lisa M. , Basse Per , Bartlett David L. , Kwon Yong Tae , Lee Yong J.
Published: April 2023

Supplementary Figure legend
Supplementary Table S3 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

Full details on antibodies used in AZD8835 studies.
Supplementary Figure 2 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo
Authors: Staudacher Alexander H. , Li Yanrui , Liapis Vasilios , Hou Jeff Jia Cheng , Chin David , Dolezal Olan , Adams Timothy E. , van Berkel Patrick H. , Brown Michael P.
Published: April 2023

chDAB4 binds within the apoptotic/necrotic regions of lung tumor xenografts.
Supplementary Table S2 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Authors: Andreev Julian , Thambi Nithya , Perez Bay Andres E. , Delfino Frank , Martin Joel , Kelly Marcus P. , Kirshner Jessica R. , Rafique Ashique , Kunz Arthur , Nittoli Thomas , MacDonald Douglas , Daly Christopher , Olson William , Thurston Gavin
Published: April 2023

In vitro Potency of HER2 ADC, PRLR ADC and HER2xPRLRbs ADC in a Panel of Breast Cancer Cell Lines
Supplementary Figure S4 from Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas
Authors: Garandeau David , Noujarède Justine , Leclerc Justine , Imbert Caroline , Garcia Virginie , Bats Marie-Lise , Rambow Florian , Gilhodes Julia , Filleron Thomas , Meyer Nicolas , Brayer Stéphanie , Arcucci Silvia , Tartare-Deckert Sophie , Ségui Bruno , Marine Jean-Christophe , Levade Thierry , Bertolotto Corine , Andrieu-Abadie Nathalie
Published: April 2023

Supplementary Figure S4 shows that MITF expression is associated to S1PR1 in PLX-treated melanoma cells
Supplementary Figure S2 from Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas
Authors: Garandeau David , Noujarède Justine , Leclerc Justine , Imbert Caroline , Garcia Virginie , Bats Marie-Lise , Rambow Florian , Gilhodes Julia , Filleron Thomas , Meyer Nicolas , Brayer Stéphanie , Arcucci Silvia , Tartare-Deckert Sophie , Ségui Bruno , Marine Jean-Christophe , Levade Thierry , Bertolotto Corine , Andrieu-Abadie Nathalie
Published: April 2023

Supplementary Figure S2 shows the plasma SL levels in patients responding or not to BRAFi
Supplementary Data from Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas
Authors: Garandeau David , Noujarède Justine , Leclerc Justine , Imbert Caroline , Garcia Virginie , Bats Marie-Lise , Rambow Florian , Gilhodes Julia , Filleron Thomas , Meyer Nicolas , Brayer Stéphanie , Arcucci Silvia , Tartare-Deckert Sophie , Ségui Bruno , Marine Jean-Christophe , Levade Thierry , Bertolotto Corine , Andrieu-Abadie Nathalie
Published: April 2023

Legends to the supplemental figures
Supplementary Table S2 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Authors: Jhuraney Ankita , Woods Nicholas T. , Wright Gabriela , Rix Lily , Kinose Fumi , Kroeger Jodi L. , Remily-Wood Elizabeth , Cress W. Douglas , Koomen John M. , Brantley Stephen G. , Gray Jhanelle E. , Haura Eric B. , Rix Uwe , Monteiro Alvaro N.
Published: April 2023

Composition of tissue microarray TMA1
Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor
Authors: Wu Tingyu , Chen Wei , Zhong Yongwang , Hou Xiaodan , Fang Shengyun , Liu Chen-Ying , Wang Guanghui , Yu Tong , Huang Yu-Yang , Ouyang Xuesong , Li Henry Q.X. , Cui Long , Yang Yili
Published: April 2023

Supplementary Figure Legends
Supplementary Materials and Methods from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Authors: Jhuraney Ankita , Woods Nicholas T. , Wright Gabriela , Rix Lily , Kinose Fumi , Kroeger Jodi L. , Remily-Wood Elizabeth , Cress W. Douglas , Koomen John M. , Brantley Stephen G. , Gray Jhanelle E. , Haura Eric B. , Rix Uwe , Monteiro Alvaro N.
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure S8 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Authors: Jhuraney Ankita , Woods Nicholas T. , Wright Gabriela , Rix Lily , Kinose Fumi , Kroeger Jodi L. , Remily-Wood Elizabeth , Cress W. Douglas , Koomen John M. , Brantley Stephen G. , Gray Jhanelle E. , Haura Eric B. , Rix Uwe , Monteiro Alvaro N.
Published: April 2023

(A) TMA containing 68 patient-derived xenograft (PDX) tumor models stained with PAXIP1 and WEE1 (B-C) Two lung adenocarcinoma PDXs with PAXIP1 and WEE1 staining were used to perform ex vivo 3-D clonogenic assays with various concentrations of AZD1775 and cisplatin and tumor/control - T/C was measured by image analysis.
Supplementary Fig.2 from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor
Authors: Wu Tingyu , Chen Wei , Zhong Yongwang , Hou Xiaodan , Fang Shengyun , Liu Chen-Ying , Wang Guanghui , Yu Tong , Huang Yu-Yang , Ouyang Xuesong , Li Henry Q.X. , Cui Long , Yang Yili
Published: April 2023

Carfilzomib and KPT330 exhibited synergistic cytotoxicity in HCT116 cells.
Supplementary Fig.1 from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor
Authors: Wu Tingyu , Chen Wei , Zhong Yongwang , Hou Xiaodan , Fang Shengyun , Liu Chen-Ying , Wang Guanghui , Yu Tong , Huang Yu-Yang , Ouyang Xuesong , Li Henry Q.X. , Cui Long , Yang Yili
Published: April 2023

The cell viability assay with different order of drug treatment.
Supplementary Figure S2 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Authors: Jhuraney Ankita , Woods Nicholas T. , Wright Gabriela , Rix Lily , Kinose Fumi , Kroeger Jodi L. , Remily-Wood Elizabeth , Cress W. Douglas , Koomen John M. , Brantley Stephen G. , Gray Jhanelle E. , Haura Eric B. , Rix Uwe , Monteiro Alvaro N.
Published: April 2023

(A-B) Lung cancer cell lines were treated with 2.5 Î¼M AZD1775 alone for 72 h and linear correlation (R2) between percentage cell viability and WEE1 and pY15-CDK1 expression was determined. (C) Immunoprecipitation of BRCA1 using a monoclonal antibody. Note that BRCA1 is shown as two light bands (hypo- and hyper phosphorylated forms) and that the antibody preferentially immunoprecipitates the hypo-phosphorylated form (faster migrating band). (D) Control western blots for PAXIP1 antibodies (#370 and #369). (E) Immunoprecipitation of PAXIP1 using #369 antibody and blotted against the #370 antibody. Ectopically expressed TAP-tagged PAXIP1 is also recognized by the #370 antibody. (F) AZD1775 does not disrupt the interaction between PAXIP1 tBRCT C2 and WEE1. (biological replicate of Figure 2E). TAP-tBRCT C2 or a TAP-GFP were ectopically expressed in 293FT cells. Equal amounts of lysates expressing TAP-tBRCT C2 were used to incubate in the presence (1 ÂµM) or absence of AZD1775 for 1 h. Lysates were pulled down with streptavidin beads and blotted against CBP to demonstrate equivalent pull down of the ectopic proteins (bottom panel). Incubation with AZD1775 slightly increased binding of WEE1 to PAXIP1 tBRCT C2 (right panel).
Supplementary Figure S1 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Authors: Jhuraney Ankita , Woods Nicholas T. , Wright Gabriela , Rix Lily , Kinose Fumi , Kroeger Jodi L. , Remily-Wood Elizabeth , Cress W. Douglas , Koomen John M. , Brantley Stephen G. , Gray Jhanelle E. , Haura Eric B. , Rix Uwe , Monteiro Alvaro N.
Published: April 2023

(A) Peak area for each peptide for a protein (exemplified by MAPK3 - ALLDLLR) as analyzed by liquid chromatography-multiple reaction monitoring (LC-MRM). Peak area for each protein (representative peptide) was ranked from 1-15 based on the levels with 1 being the highest level and 15 being the lowest level (B) Heatmap indicating the cell line ranking for each kinase to assess the relative expression level of each kinase in the 15 cell lines. Cell lines were ranked from 1 to 15. (C) WEE1, pY15-CDK1, and total CDK1 levels in 21 untreated log growing lung cancer cell lines. (D) Dose-response curves of three lung cancer cell lines with varying expression of WEE1. The cell lines expressing WEE1 had significantly lower IC50s than those with no expression of WEE1 (H322: 0.45 ï�­M, H1648: 1.23 ï�­M, H1395: >10 ï�­M, %RLU - Relative light units measuring ATP).
Supplementary figures and table from Sensitization of EGFR Wild-Type Non–Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
Authors: Raimbourg Judith , Joalland Marie-Pierre , Cabart Mathilde , de Plater Ludmilla , Bouquet Fanny , Savina Ariel , Decaudin Didier , Bennouna Jaafar , Vallette François M. , Lalier Lisenn
Published: April 2023

Supplementary figures and table described in the manuscript
Supplementary figure 1 from In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment
Authors: Pérez-Peña Javier , Serrano-Heras Gemma , Montero Juan Carlos , Corrales-Sánchez Verónica , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

A) JQ1 and OTX015 inhibitory action, as the IC50, calculated after 48 and 72 hours of treatment using MTT assay as described in "Material and methods". 2B) Antiproliferative effect of JQ1 in semi-solid MDA-MB-231 cultures. Cells (25,000/ml) were plated in 48 multiwell plates and grown in medium containing 2% matrigel in the presence of JQ1 (0.2ÂµM), cisplatin (2.5 ÂµM) and docetaxel (0.5nM) alone and in combination for 3 days. All images were taken at Ã-20 magnification. The quantification of sphere diameter was performed manually by tracing a straight line across the sphere diameter of untreated cells (controls) and scoring its value as arbitrary length units. Total number of colonies per plate was manually counted.
Figure S1 from A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
Authors: Garcia Tamara B. , Snedeker Jonathan C. , Baturin Dmitry , Gardner Lori , Fosmire Susan P. , Zhou Chengjing , Jordan Craig T. , Venkataraman Sujatha , Vibhakar Rajeev , Porter Christopher C.
Published: April 2023

Single agent treatment with olaparib or AZD1775 reduces cell viability and enhances apoptosis in AML and ALL cell lines. A. MV4;11, Molm13, Jurkat, and REH cells were treated with 0.25 uM- 20 uM olaparib for 72 hr. Percent of viable cells relative to cells receiving no treatment (NT) are shown. The IC50 value of each cell line is displayed. B. MV4;11, Molm13, Jurkat, and REH cells were treated with 0.25 uM- 20 uM olaparib for 72 hr and stained with Annexin V-PE. The EC50 value of each cell line is displayed. C. MV4;11, Molm13, Jurkat, and REH cells were treated with 25 nM - 2000 nM AZD1775 for 72 hr. Percent of viable cells relative to cells receiving no treatment (NT) are shown. The IC50 value of each cell line is displayed. D. MV4;11, Molm13, Jurkat, and REH cells were treated with 25 nM - 2000 nM AZD1775 for 72 hr and stained with Annexin V-PE. The EC50 value of each cell line is displayed.
Figure S2 from Glycoprotein-130 Expression Is Associated with Aggressive Bladder Cancer and Is a Potential Therapeutic Target
Authors: Martin Darryl T. , Shen Hongliang , Steinbach-Rankins Jill M. , Zhu Xi , Johnson Katelyn K. , Syed Jamil , Saltzman W. Mark , Weiss Robert M.
Published: April 2023

Fig S2. Cell growth of bladder cancer cells upon SC144 treatment.
Figure S1 from Glycoprotein-130 Expression Is Associated with Aggressive Bladder Cancer and Is a Potential Therapeutic Target
Authors: Martin Darryl T. , Shen Hongliang , Steinbach-Rankins Jill M. , Zhu Xi , Johnson Katelyn K. , Syed Jamil , Saltzman W. Mark , Weiss Robert M.
Published: April 2023

Fig S1. Dose-response curve of bladder cancer cells upon SC144 treatment.
Supplementary figure legends from TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation
Authors: Lee Younghyun , Sunada Shigeaki , Hirakawa Hirokazu , Fujimori Akira , Nickoloff Jac A. , Okayasu Ryuichi
Published: April 2023

Supplementary figure legends (S1-S7)
Supplementary figure S1-S7 from TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation
Authors: Lee Younghyun , Sunada Shigeaki , Hirakawa Hirokazu , Fujimori Akira , Nickoloff Jac A. , Okayasu Ryuichi
Published: April 2023

Supplementary figure S1. Structure of TAS-116., Supplementary figure S2. TAS-116 inhibits DSB repair in irradiated H1299 cells., Supplementary figure S3. TAS-116 induces G2/M arrest in H1299 cells., Supplementary figure S4. Cell cycle distribution considering dead cell by TAS-116., Supplementary figure S5. Combined treatment with TAS-116 and irradiation does not synergistically increase sub-G1 cell population in HeLa cells., Supplementary figure S6. Combined treatment with TAS-116 and irradiation does not synergistically increase the expression levels of cleaved PARP and caspase 3 in HeLa cells., Supplementary figure S7. Combined treatment with TAS-116 and carbon ions decreased tumor size in a HeLa xenograft mouse model.
Supplementary Table S1 and Supplementary Figures S1-S4 from Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor
Authors: Bonnevaux Hélène , Lemaitre Olivier , Vincent Loic , Levit Mikhail N. , Windenberger Fanny , Halley Frank , Delorme Cécile , Lengauer Christoph , Garcia-Echeverria Carlos , Virone-Oddos Angela
Published: April 2023

Supplementary Tables S1. Table S1 describes the inhibitory activity of SAR260301 on AKT phosphorylation (Ser473 and Thr308) in a panel of tumor cell lines with different genetic abnormalities that are reported. Supplementary Figures S1-S4. Figure S1 illustrates the selectivity of SAR260301 against VPS34 in cellular setting: Figure S1A describes the activity of SAR260301 on VPS34 kinase function in GFP-FYVE cellular assay; Figure S1B describes the activity of SAR260301 on autophagy in GFP-LC3 cellular assays. Figure S2 describes the inhibitory activity of SAR260301 on the phosphorylation of AKT downstream effectors PRAS40 and S6RP in PC3 cell line, as a function of time. Figure S3 describes the in vitro antitumor activity of SAR260301: Figure S3A describes the antiproliferative activity of SAR260301on MEF-3T3-myr p110Î² cells. Figure S3B describes the antiproliferative activity of SAR260301on PC3 cells. Figure S3C describes the activity of SAR260301on PC3 cell death. Figure S3D describes the activity of SAR260301on LnCaP cell apoptosis. Figure S4 is a scheme describing the rationale for combining inhibitors of PI3Kï�¢ and MAPK.
Supplemental Table 4 from Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R
Authors: de Lint Klaas , Poell Jos B. , Soueidan Hayssam , Jastrzebski Katarzyna , Vidal Rodriguez Jordi , Lieftink Cor , Wessels Lodewyk F.A. , Beijersbergen Roderick L.
Published: April 2023

The correlation between Î"AUC and IGF1R mRNA and protein
Supplementary Figure 3 from Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
Authors: Chen Jun , Kinoshita Taisei , Sukbuntherng Juthamas , Chang Betty Y. , Elias Laurence
Published: April 2023

Supplementary Figure S3. Response of cell signaling pathways to treatment with ibrutinib in multiple cell lines. Cells were treated for 1 hour with ibrutinib. 50,000 cells were loaded in each lane.
Supplementary Figure 1 from Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
Authors: Chen Jun , Kinoshita Taisei , Sukbuntherng Juthamas , Chang Betty Y. , Elias Laurence
Published: April 2023

Supplementary Figure S1. Response of MDA-MB-361 cells to multiple inhibitors. MD-MB-361 cells were plated in 96-well plates overnight before treatment with inhibitors for 72 hours. CellTiter-GloÂ® was used for quantifying cell growth. The assay was repeated 3 times, and the error bars represent SD.
Table S1 from Combined PPARγ Activation and XIAP Inhibition as a Potential Therapeutic Strategy for Ovarian Granulosa Cell Tumors
Authors: Leung Dilys T.H. , Nguyen Trang , Oliver Edwina May , Matti Juliana , Alexiadis Maria , Silke John , Jobling Thomas W. , Fuller Peter J. , Chu Simon
Published: April 2023

Table S1. Gene expression analysis by TaqMan Low-Density Array.
Figure S3 from Combined PPARγ Activation and XIAP Inhibition as a Potential Therapeutic Strategy for Ovarian Granulosa Cell Tumors
Authors: Leung Dilys T.H. , Nguyen Trang , Oliver Edwina May , Matti Juliana , Alexiadis Maria , Silke John , Jobling Thomas W. , Fuller Peter J. , Chu Simon
Published: April 2023

Figure S3. Effects of XIAP inhibition alone or in combination with PPARg activation.
Figure S1 from Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line–Specific Effects from P-Glycoprotein–Induced Toxicity
Authors: Füredi András , Tóth Szilárd , Szebényi Kornélia , Pape Veronika F.S. , Türk Dóra , Kucsma Nóra , Cervenak László , Tóvári József , Szakács Gergely
Published: April 2023

Supplementary Figure 1: MDR-selective toxicity of NSC297366 in additional MDR cell lines
Supplementary Table S1 from Chromatin Regulators as a Guide for Cancer Treatment Choice
Authors: Gurard-Levin Zachary A. , Wilson Laurence O.W. , Pancaldi Vera , Postel-Vinay Sophie , Sousa Fabricio G. , Reyes Cecile , Marangoni Elisabetta , Gentien David , Valencia Alfonso , Pommier Yves , Cottu Paul , Almouzni Geneviève
Published: April 2023

Clinical characteristics of the Institut Curie patient cohort
Supplemental Figure 2 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Authors: Thibault Stephane , Hu Wenyue , Hirakawa Brad , Kalabat Dalia , Franks Tania , Sung Tae , Khoh-Reiter Su , Lu Shuyan , Finkelstein Martin , Jessen Bart , Sacaan Aida
Published: April 2023

Figure S2 shows A) significantly perturbed genes, B) Venn diagram of changed genes, C) hierarchical clustering of changed genes, D) volcano plot of all genes.
Supplemental Figure 1 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Authors: Thibault Stephane , Hu Wenyue , Hirakawa Brad , Kalabat Dalia , Franks Tania , Sung Tae , Khoh-Reiter Su , Lu Shuyan , Finkelstein Martin , Jessen Bart , Sacaan Aida
Published: April 2023

Figure S1 shows duodenum stained with PAS/Alcian blue, and TEM from jejunum.
Supplementary Table S2 from An Artificially Designed Interfering lncRNA Expressed by Oncolytic Adenovirus Competitively Consumes OncomiRs to Exert Antitumor Efficacy in Hepatocellular Carcinoma
Authors: Li Xiaoya , Su Yinghan , Sun Bin , Ji Weidan , Peng Zhangxiao , Xu Yang , Wu Mengchao , Su Changqing
Published: April 2023

Adenovirus-expressed lncRNAi affects gene expression profiles in HCC cells
Supp Table 1 from Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
Authors: Bisi John E. , Sorrentino Jessica A. , Roberts Patrick J. , Tavares Francis X. , Strum Jay C.
Published: April 2023

Target Genes with greater than 90% inhibition at 100nM
Supplementary Methods from Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen
Authors: Wang Xinning , Tsui Brian , Ramamurthy Gopolakrishnan , Zhang Ping , Meyers Joseph , Kenney Malcolm E. , Kiechle Jonathan , Ponsky Lee , Basilion James P.
Published: April 2023

HPLC condition details and method for the determination of light spctra and radiant exposure
Supp Figure 2 from Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
Authors: Bisi John E. , Sorrentino Jessica A. , Roberts Patrick J. , Tavares Francis X. , Strum Jay C.
Published: April 2023

G1T28 shows a dose-dependent decrease in cycling bone marrow cells in beagle dogs with minimal changes in peripheral blood neutrophils and RBCs after one G1T28 treatment.
Supp Figure 1 from Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
Authors: Bisi John E. , Sorrentino Jessica A. , Roberts Patrick J. , Tavares Francis X. , Strum Jay C.
Published: April 2023

RB status is a reliable biomarker for CDK4/6 dependence and therefore G1T28 responsiveness in vitro.
Supplementary Methods from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
Authors: Onion David , Argent Richard H. , Reece-Smith Alexander M. , Craze Madeleine L. , Pineda Robert G. , Clarke Philip A. , Ratan Hari L. , Parsons Simon L. , Lobo Dileep N. , Duffy John P. , Atherton John C. , McKenzie Andrew J. , Kumari Rajendra , King Peter , Hall Brett M. , Grabowska Anna M.
Published: April 2023

Supplementary methods: Labelling of CAFs with Td-Tom, Determining purity of epithelial cells, Imaging and staining of 3D-TGA.
Supplementary Figure Legends from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
Authors: Onion David , Argent Richard H. , Reece-Smith Alexander M. , Craze Madeleine L. , Pineda Robert G. , Clarke Philip A. , Ratan Hari L. , Parsons Simon L. , Lobo Dileep N. , Duffy John P. , Atherton John C. , McKenzie Andrew J. , Kumari Rajendra , King Peter , Hall Brett M. , Grabowska Anna M.
Published: April 2023

Legends for the supplementary figures
Supplementary table 1 from Long Noncoding RNA PVT1 Promotes Non–Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression
Authors: Wan Li , Sun Ming , Liu Guo-Jian , Wei Chen-Chen , Zhang Er-Bao , Kong Rong , Xu Tong-Peng , Huang Ming-De , Wang Zhao-Xia
Published: April 2023

Primers and siRNA sequences
Supplementary Figure 7 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
Authors: Onion David , Argent Richard H. , Reece-Smith Alexander M. , Craze Madeleine L. , Pineda Robert G. , Clarke Philip A. , Ratan Hari L. , Parsons Simon L. , Lobo Dileep N. , Duffy John P. , Atherton John C. , McKenzie Andrew J. , Kumari Rajendra , King Peter , Hall Brett M. , Grabowska Anna M.
Published: April 2023

Drug sensitivity of NSCLC specimens to HDAC inhibitors and combination with standards of care.
Supplementary Table S3 from A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers
Authors: Cho Sung-Yup , Han Jee Yun , Na Deukchae , Kang Wonyoung , Lee Ahra , Kim Jooyoung , Lee Jieun , Min Seoyeon , Kang Jinjoo , Chae Jeesoo , Kim Jong-Il , Park Hansoo , Lee Won-Suk , Lee Charles
Published: April 2023

Supplementary Table S3. List of 737 genes significantly altered in combination treatment of ABT-263 and YM-155 compared to other samples (P < 0.05).
Supplementary Table S2 from A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers
Authors: Cho Sung-Yup , Han Jee Yun , Na Deukchae , Kang Wonyoung , Lee Ahra , Kim Jooyoung , Lee Jieun , Min Seoyeon , Kang Jinjoo , Chae Jeesoo , Kim Jong-Il , Park Hansoo , Lee Won-Suk , Lee Charles
Published: April 2023

FPKM expression values of 2223 genes deregulated in response to treatment in at least one condition compared to control (P < 0.05)
Supplementary Figure 1 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
Authors: Onion David , Argent Richard H. , Reece-Smith Alexander M. , Craze Madeleine L. , Pineda Robert G. , Clarke Philip A. , Ratan Hari L. , Parsons Simon L. , Lobo Dileep N. , Duffy John P. , Atherton John C. , McKenzie Andrew J. , Kumari Rajendra , King Peter , Hall Brett M. , Grabowska Anna M.
Published: April 2023

The purity of human epithelial tumour cells entered into the 3D-TGA.
Supplementary Table 1-Patient data from Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer
Authors: Kozyreva Varvara K. , Kiseleva Anna A. , Ice Ryan J. , Jones Brandon C. , Loskutov Yuriy V. , Matalkah Fatimah , Smolkin Matthew B. , Marinak Kristina , Livengood Ryan H. , Salkeni Mohamad A. , Wen Sijin , Hazard Hannah W. , Layne Ginger P. , Walsh Callee M. , Cantrell Pamela S. , Kilby Greg W. , Mahavadi Sricharan , Shah Neal , Pugacheva Elena N.
Published: April 2023

Table contains diagnostics/characterization of original and patient-derived models.
Supplementary Figures S1-S4 with Legends from Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma
Authors: Stiff Andrew , Caserta Enrico , Sborov Douglas W. , Nuovo Gerard J. , Mo Xiaokui , Schlotter Sarah Y. , Canella Alessandro , Smith Emily , Badway Joseph , Old Matthew , Jaime-Ramirez Alena Cristina , Yan Pearlly , Benson Don M. , Byrd John C. , Baiocchi Robert , Kaur Balveen , Hofmeister Craig C. , Pichiorri Flavia
Published: April 2023

Supplementary Fig. S1. Therapeutic efficacy of RV and HDACi against cancer B cells; Supplementary Fig. S2. HDACi increase JAM-1 expression without affecting cell viability; Supplementary Fig. S3. RV+HDACi display synergistic anti-myeloma activity; Supplementary Fig. S4. Combination treatment of MCL cells with RV and HDAC inhibitors results in increased cell death, compared to single agent treatments.
Supplementary Table 1 from Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation
Authors: Flores M. Luz , Castilla Carolina , Gasca Jessica , Medina Rafael , Pérez-Valderrama Begoña , Romero Francisco , Japón Miguel A. , Sáez Carmen
Published: April 2023

Correlation between the expression of PKCÎ', active Î²-catenin, AurKA, phospho-GSK3Î²Ser9 and Mcl-1 with Gleason score and with one another.
Supplement Information - Revised from Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells
Authors: Souchek Joshua J. , Davis Amanda L. , Hill Tanner K. , Holmes Megan B. , Qi Bowen , Singh Pankaj K. , Kridel Steven J. , Mohs Aaron M.
Published: April 2023

Supplementary Figure S1. Dose-response curves of combinations of orlistat or NanoOrl with taxanes; Supplementary Figure S2. Synergy analysis with Combenefit (Loewe model);Supplementary Figure S3. Synergy analysis with Combenefit [Highest Single Agent (HSA) model];Supplementary Figure. S4. Morphological changes associated with combination treatment;Supplementary Figure S5. Combination of NanoOrl plus docetaxel stabilizes microtubules in taxane-resistant cells;Supplementary Fig. S6. Example of overestimation of synergy; Supplementary Fig. S7. Example of underestimation of synergy.